Mankind Pharma Limited has successfully completed its payment obligations for three series of Non-Convertible Debentures (NCDs) on April 16, 2026. The company fulfilled both interest payments for all three ISINs and executed the full redemption of its ₹1,250 crore NCD issuance. This timely settlement marks the final maturity for the redeemed series, underscoring the company’s robust financial position and commitment to its debt obligations.
Interest Payment Overview
On April 16, 2026, Mankind Pharma processed interest payments for three distinct NCD series: INE634S07017, INE634S07025, and INE634S07033. The gross interest distributed amounted to ₹498,006,855, ₹498,006,853, and ₹993,520,559 respectively. All payments were made following the April 1, 2026 record date, confirming the company’s adherence to its semi-annual interest payment schedule.
Successful Redemption of NCDs
In addition to the interest distribution, Mankind Pharma achieved the full redemption of its ₹1,250 crore NCD series (ISIN: INE634S07017) upon its scheduled maturity on April 16, 2026. A total of 1,25,000 NCDs were retired, bringing the outstanding amount for this series to zero. This milestone represents a clean closure of the debt instrument, reflecting the company’s disciplined approach to capital management and financial stability.
Source: BSE
